Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer

Oncology Letters

Volumn 8, Issue 1, 2014, Pages 25-32

  Abat, Deniz ^a   Demirhan, Osman ^a   Inandiklioglu, Nihal ^a   Tunc, Erdal ^a   Erdogan, Seyda ^a   Tastemir, Deniz ^b   Uslu, Inayet Nur ^a   Tansug, Zuhtu ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

^b ADIYAMAN UNIVERSITY   (Turkey)

Author keywords

Bladder carcinoma; Chromosomal aberrations; Fluorescence in situ hybridization; High grade; Low grade; p16; p53

Indexed keywords

PROTEIN P16; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER TISSUE; CARCINOMA IN SITU; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHROMOSOME FRAGILITY; CHROMOSOME STRUCTURE; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; MONOSOMY; VERY ELDERLY;

EID: 84901237250     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2108     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Jacobs BL, Lee CT and Montie JE: Bladder cancer in 2010: how far have we come? CA Cancer J Clin 60: 244-272, 2010.
3. Sullivan PS, Chan JB, Levin MR and Rao J: Urine cytology and adjunct markers for detection and surveillance of bladder cancer. Am J Trans Res 2: 412-440, 2010.
4. Vrooman OP and Witjes JA: Molecular markers for detection, surveillance and prognostication of bladder cancer. Int J Urol 16: 234-243, 2009.
5. Habuchi T, Marberger M, Droller MJ, et al: Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 66 (Suppl 1): 64-74, 2005.
6. Proctor I, Stoeber K and Williams GH: Biomarkers in bladder cancer. Histopathology 57: 1-13, 2010.
7. Lin HH, Ke HL, Huang SP, Wu WJ, Chen YK and Chang LL: Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. Urol Oncol 28: 597-602, 2010.
8. Knowles MA: The genetics of transitional cell carcinoma: progress and potential clinical application. BJU Int 84: 412-427, 1999.
9. Cianciulli AM, Leonardo C, Guadagni F, et al: Genetic instability in superficial bladder cancer and adjacent mucosa: an interphase cytogenetic study. Hum Pathol 34: 214-221, 2003.
10. Eble JN, Sauter G, Epstein JI and Sesterhenn I (eds): WHO Classification of Tumours Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press, Lyon, pp90-91, 2004.
11. Fundia AF and Larripa IB: Coincidence in fragile site expression with fluorodeoxyuridine and bromodeoxyuridine. Cancer Genet Cytogenet 41: 41-48, 1989.
12. Mitelman F (ed): ISCN: An International System for Human Cytogenetics Nomenclature. S. Karger, Basel, 1995.
13. McAlpine PJ, Shows TB, Boucheli C, Huebner M and Anderson WA: The 1991 catalog of mapped genes and report of the nomenclature committee, Human Gene Mapping 11. Cytogenet Cell Genet 58: 5-102, 1991.
14. Trask B and Pinkel D: Fluorescence in situ hybridization with DNA probes. Methods Cell Biol 33: 383-400, 1990.
15. Junker K, van Oers JM, Zwarthoff EC, Kania I, Schubert J and Hartmann A: Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia 10: 1-7, 2008.
16. Wolff DJ: The genetics of bladder cancer: a cytogeneticist's perspective. Cytogenet Genome Res 118: 177-181, 2007.
17. Tommasi S, Dammann R, Jin SG, Zhang XF, Avruch J and Pfeifer GP: RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene 18: 21: 2713-2720, 2002.
18. Caramazza D, Hussein K, Siragusa S, et al: Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations. Eur J Haematol 84: 191-200, 2010.
19. Ichimura Y, Habuchi T, Tsuchiya N, et al: Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant. J Urol 172: 728-732, 2004.
20. Awakura Y, Nakamura E, Ito N, Kamoto T and Ogawa O: Methylation-associated silencing of TU3A in human cancers. Int J Oncol 33: 893-899, 2008.
21. Duns G, van den Berg E, van Duivenbode I, et al: Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res 1: 70: 4287-4291, 2010.
22. Angeloni D: Molecular analysis of deletions in human chromosome 3p21 and the role of resident cancer genes in disease. Brief Funct Genomic Proteomic 6: 19-39, 2007.
23. Jarmalaite S, Jankevicius F, Kurgonaite K, Suziedelis K, Mutanen P and Husgafvel-Pursiainen K: Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology 75: 145-151, 2008.
24. Dammann R, Schagdarsurengin U, Seidel C, et al: The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 20: 645-663, 2005.
25. Dallosso AR, Hancock AL, Szemes M, et al: Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor. PLoS Genet 5: 1000745, 2009.
26. Kanetsky PA, Mitra N, Vardhanabhuti S, et al: Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet 41: 811-815, 2009.
27. Nakazawa K, Murata S, Yuminamochi T, et al: p16(INK4a) expression analysis as an ancillary tool for cytologic diagnosis of urothelial carcinoma. Am J Clin Pathol 132: 776-784, 2009.
28. Chang LL, Yeh WT, Yang SY, Wu WJ and Huang CH: Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer. J Urol 170: 595-600, 2003.
29. Krüger S, Mahnken A, Kausch I and Feller AC: P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur Urol 47: 463-467, 2005.
30. Moonen PM, van Balken-Ory B, Kiemeney LA, Schalken JA and Witjes JA: Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J Urol 177: 80-83, 2007.
31. Smith ND, Rubenstein JN, Eggener SE and Kozlowski JM: The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol 169: 1219-1228, 2003.
32. Malats N, Bustos A, Nascimento CM, et al: P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6: 678-686, 2005.
33. Shariat SF, Chade DC, Karakiewicz PI, et al: Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 183: 68-75, 2010.